Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers.
Colorectal cancer
Genome wide DNA methylation
Lynch syndrome
MLH1 epimutation
MLH1 methylation
MMR deficiency
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
03 06 2023
03 06 2023
Historique:
received:
16
01
2023
accepted:
24
05
2023
medline:
5
6
2023
pubmed:
4
6
2023
entrez:
3
6
2023
Statut:
epublish
Résumé
MLH1 epimutation is characterised by constitutional monoallelic MLH1 promoter hypermethylation, which can cause colorectal cancer (CRC). Tumour molecular profiles of MLH1 epimutation CRCs were used to classify germline MLH1 promoter variants of uncertain significance and MLH1 methylated early-onset CRCs (EOCRCs). Genome-wide DNA methylation and somatic mutational profiles of tumours from two germline MLH1: c.-11C > T and one MLH1: c.-[28A > G; 7C > T] carriers and three MLH1 methylated EOCRCs (< 45 years) were compared with 38 reference CRCs. Methylation-sensitive droplet digital PCR (ddPCR) was used to detect mosaic MLH1 methylation in blood, normal mucosa and buccal DNA. Genome-wide methylation-based Consensus Clustering identified four clusters where the tumour methylation profiles of germline MLH1: c.-11C > T carriers and MLH1 methylated EOCRCs clustered with the constitutional MLH1 epimutation CRCs but not with the sporadic MLH1 methylated CRCs. Furthermore, monoallelic MLH1 methylation and APC promoter hypermethylation in tumour were observed in both MLH1 epimutation and germline MLH1: c.-11C > T carriers and MLH1 methylated EOCRCs. Mosaic constitutional MLH1 methylation in MLH1: c.-11C > T carriers and 1 of 3 MLH1 methylated EOCRCs was identified by methylation-sensitive ddPCR. Mosaic MLH1 epimutation underlies the CRC aetiology in MLH1: c.-11C > T germline carriers and a subset of MLH1 methylated EOCRCs. Tumour profiling and ultra-sensitive ddPCR methylation testing can be used to identify mosaic MLH1 epimutation carriers.
Sections du résumé
BACKGROUND
MLH1 epimutation is characterised by constitutional monoallelic MLH1 promoter hypermethylation, which can cause colorectal cancer (CRC). Tumour molecular profiles of MLH1 epimutation CRCs were used to classify germline MLH1 promoter variants of uncertain significance and MLH1 methylated early-onset CRCs (EOCRCs). Genome-wide DNA methylation and somatic mutational profiles of tumours from two germline MLH1: c.-11C > T and one MLH1: c.-[28A > G; 7C > T] carriers and three MLH1 methylated EOCRCs (< 45 years) were compared with 38 reference CRCs. Methylation-sensitive droplet digital PCR (ddPCR) was used to detect mosaic MLH1 methylation in blood, normal mucosa and buccal DNA.
RESULTS
Genome-wide methylation-based Consensus Clustering identified four clusters where the tumour methylation profiles of germline MLH1: c.-11C > T carriers and MLH1 methylated EOCRCs clustered with the constitutional MLH1 epimutation CRCs but not with the sporadic MLH1 methylated CRCs. Furthermore, monoallelic MLH1 methylation and APC promoter hypermethylation in tumour were observed in both MLH1 epimutation and germline MLH1: c.-11C > T carriers and MLH1 methylated EOCRCs. Mosaic constitutional MLH1 methylation in MLH1: c.-11C > T carriers and 1 of 3 MLH1 methylated EOCRCs was identified by methylation-sensitive ddPCR.
CONCLUSIONS
Mosaic MLH1 epimutation underlies the CRC aetiology in MLH1: c.-11C > T germline carriers and a subset of MLH1 methylated EOCRCs. Tumour profiling and ultra-sensitive ddPCR methylation testing can be used to identify mosaic MLH1 epimutation carriers.
Identifiants
pubmed: 37270516
doi: 10.1186/s13148-023-01511-y
pii: 10.1186/s13148-023-01511-y
pmc: PMC10239107
doi:
Substances chimiques
Carbon-11
0
DNA
9007-49-2
MLH1 protein, human
0
MutL Protein Homolog 1
EC 3.6.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Subventions
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Nucleic Acids Res. 2007;35(6):e41
pubmed: 17289753
Fam Cancer. 2016 Jul;15(3):413-22
pubmed: 26886015
J Gastroenterol Hepatol. 2017 Feb;32(2):427-438
pubmed: 27273229
Cancer Prev Res (Phila). 2009 Oct;2(10):862-7
pubmed: 19789298
Nucleic Acids Res. 2013 Apr;41(7):e90
pubmed: 23476028
J Mol Diagn. 2023 Feb;25(2):94-109
pubmed: 36396080
Cancer Cell. 2011 Aug 16;20(2):200-13
pubmed: 21840485
Gastroenterology. 2019 Oct;157(4):949-966.e4
pubmed: 31323292
Int J Cancer. 2006 Nov 15;119(10):2272-8
pubmed: 16981189
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Oncotarget. 2017 Jan 31;8(5):7452-7463
pubmed: 27980218
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Cancers (Basel). 2021 May 25;13(11):
pubmed: 34070516
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28423402
Epigenetics Chromatin. 2015 Jan 27;8:6
pubmed: 25972926
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
J Pathol. 2013 Jun;230(2):148-53
pubmed: 23447401
Nucleic Acids Res. 2000 Apr 15;28(8):E32
pubmed: 10734209
Gut. 2019 Apr;68(4):761-762
pubmed: 29574407
Clin Genet. 2014 May;85(5):413-6
pubmed: 24588205
J Med Genet. 2022 Apr;59(4):318-327
pubmed: 33622763
J Med Genet. 2019 Jul;56(7):462-470
pubmed: 30877237
J Med Genet. 2018 Apr;55(4):240-248
pubmed: 29472279
J Gastroenterol. 2013 Mar;48(3):287-302
pubmed: 23208018
Cancer Cell. 2019 Feb 11;35(2):315-328.e6
pubmed: 30753828
J Med Genet. 2011 Aug;48(8):513-9
pubmed: 21712435
Cancer Med. 2018 Feb;7(2):433-444
pubmed: 29341452
Eur J Hum Genet. 2012 Dec;20(12):1256-64
pubmed: 22763379
Nat Rev Cancer. 2015 Oct;15(10):625-34
pubmed: 26383139
Genet Med. 2013 Jan;15(1):25-35
pubmed: 22878509
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Genet Med. 2018 Dec;20(12):1589-1599
pubmed: 29790873
JAMA Oncol. 2015 Oct;1(7):953-7
pubmed: 26181641
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):710-5
pubmed: 10639144
BMC Bioinformatics. 2010 Nov 30;11:587
pubmed: 21118553
Int J Epidemiol. 2018 Apr 1;47(2):387-388i
pubmed: 29490034
Clin Epigenetics. 2019 Nov 28;11(1):171
pubmed: 31779681
Gut. 2021 Nov;70(11):2138-2149
pubmed: 33414168
Oncogene. 2018 Feb 1;37(5):566-577
pubmed: 28991233
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Methods Mol Biol. 2018;1768:363-383
pubmed: 29717454
Cancer Res. 1999 May 1;59(9):2029-33
pubmed: 10232580
J Med Genet. 2009 Dec;46(12):793-802
pubmed: 19564652
Genome Biol. 2014 Dec 03;15(12):503
pubmed: 25599564
Hum Mol Genet. 2012 Nov 1;21(21):4669-79
pubmed: 22843497
J Med Genet. 2012 Mar;49(3):151-7
pubmed: 22368298
Gut. 2019 Apr;68(4):684-692
pubmed: 29666172
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Genes Chromosomes Cancer. 2009 Aug;48(8):737-44
pubmed: 19455606
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Am J Surg Pathol. 2013 Oct;37(10):1592-602
pubmed: 23797718
Fam Cancer. 2013 Jun;12(2):189-205
pubmed: 23462881
Breast Cancer Res. 2008;10(1):R12
pubmed: 18269736
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Hum Mutat. 2016 May;37(5):417-26
pubmed: 26888055
Hum Mutat. 2015 Jun;36(6):622-30
pubmed: 25762362